louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04636866: The Prevalence of Helicobacter Pylori in Shanghai, 2013 to 2019
Official title: The Prevalence of Helicobacter Pylori Infection in Patients With Peptic Ulcer Disease in Shanghai, 2013 to 2019
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Peptic Ulcer
Helicobacter Pylori Infection
Lead sponsor: Shanghai Jiao Tong University School of Medicine
Sponsor class: OTHER
First posted: 2020-11-19
Enrollment: 400000
Sex: ALL
Minimum age (years): 14
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: We retrieved the medical records of all patients who had undergone upper gastrointestinal endoscopy because of uninvestigated dyspepsia from January 1, 2013 through December 31, 2019.

Brief summary: The study was a cross-sectional single-center study, conducted at Renji Hospital, Shanghai Jiaotong university school of medicine. We retrieved the medical records of all patients who had undergone upper gastrointestinal endoscopy from January 1, 2013 through December 31, 2019. The medical records were analyzed for the prevalence of H. pylori infection in patients with peptic ulcers.


Eligibility criteria: Inclusion Criteria:

All patients who had undergone upper gastrointestinal endoscopy in Renji Hospital because of uninvestigated dyspepsia during 2013 and 2019 were analyzed.

Exclusion Criteria:

Patients that underwent upper endoscopy for reasons other than uninvestigated dyspepsia such as cirrhosis follow-up, major systemic diseases or other indications were excluded. Exclusions also included absence of biopsies, unknown H. pylori status and acute ulcer bleeding.

Primary outcomes:
measure: the prevalence of Helicobacter pylori and peptic ulcer
timeFrame: 2013.1.1-2019.12.31
measure: the ration of Helicobacter pylori positive peptic ulcers
timeFrame: 2013.1.1-2019.12.31
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Renji Hospital, School of Medicine, Shanghai Jiao Tong University
state: Shanghai
Study officials:
affiliation: RenJi Hospital
name: HONG LU, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT05477966: A Retrospective Cohort Study to Develop Markers for TB Severity and Treatment Progress
Official title: A Retrospective Cohort Study to Develop Markers for TB Severity and Treatment Progress
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Pulmonary Tuberculoses
Tuberculosis, Pulmonary
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2022-07-28
Enrollment: 900
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Up to 900 patients diagnosed with rifampin-susceptible pulmonary tuberculosis through the Xpert MTB/RIF assay performed on sputum between January 1, 2019 and December 31, 2019 at the participating institutions

Brief summary: The objective of this study is to compare how accurately the Xpert MTB/RIF assay Ct value at diagnosis and the AI-based tuberculosis activity score predict the treatment outcome of rifampin-susceptible pulmonary tuberculosis patients. As a retrospective observational study, data from patients diagnosed with rifampin susceptible pulmonary tuberculosis through the Xpert MTB/RIF assay performed on sputum in 2019 at the participating institutions will be analyzed (up to 900 people).


Eligibility criteria: Inclusion Criteria:

* Patients diagnosed with rifampin-susceptible pulmonary tuberculosis by Xpert MTB/RIF assay with sputum samples between January 1, 2019 and December 31, 2019

Exclusion Criteria:

* None

Primary outcomes:
measure: Negative culture conversion until 8 weeks after initiation of treatment
timeFrame: Within 8 weeks of initiating treatment
measure: Time to negative culture conversion
timeFrame: Within 6 months of initiating treatment
measure: Treatment outcome including 1) Cure 2) Treatment completion 3) Treatment failure 4) Death 5) Loss of follow-up 6) Unknown
timeFrame: Within 2 years of initiating treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University
Study officials:
affiliation: Seoul National University Hospital
name: Jae-Joon Yim, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02603666: Elastography of the Liver in Cystic Fibrosis Patients. Diagnostic and Prognostic Aspects
Official title: Elastography of the Liver in Cystic Fibrosis Patients. Diagnostic and Prognostic Aspects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cystic Fibrosis
Liver Fibrosis
Keywords: cystic fibrosis
elastography
liver biopsy
Lead sponsor: Karolinska University Hospital
Sponsor class: OTHER
Collaborators: name: Karolinska Institutet
First posted: 2015-11-13
Enrollment: 130
Sex: ALL
Minimum age (years): 1
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The aim of the study is to find CF patients at risk for cystic fibrosis related liver disease (CFLD). Comparison of ultrasound by two modalities and biochemical markers with histological evaluation of liver biopsy if present.

Detailed description: There are 209 CF patients attending Stockholm Cystic Fibrosis Center (January 2010). All up till 15 years of age are screened for liver disease annually by ultrasound (US) and also by biochemical markers. Ultrasound is performed every third year over 15 years of age in patients without CFLD, while all of them with diagnosed CFLD are continued to be investigated annually. Biochemical markers are controlled at least once every year in all CF patients. Elastography of the liver will be planned together with the investigations of the annual follow up, in an optimal clinical status. If either US or elastography of the liver indicates liver disease or progress of the already existing pathological changes, a liver biopsy will be performed according to routine procedure at Stockholm CF Centre. Also, historical data of liver biopsies and biochemical investigations will be considered in the study.

Elastography of the liver will be performed by Fibroscan device, with transducers for children and adults, respectively.

Clinical importance Liver US investigations in CF patients have important implications but are difficult to standardize in a routine clinical setting. Elastography may have an advantage in the evaluation of early fibrosis with clinical importance in pursuing diagnostics and intensifying treatment. A significant group (up to 25 %) of CF patients may be helped by this novel method. Including histological data, accuracy of elastography in CF patients may be improved. Further details of the importance of fatty acid status in CF may be elucidated.

Eligibility criteria: Inclusion Criteria:

* Verified cystic fibrosis

Exclusion Criteria:

Primary outcomes:
measure: Elastographic Value in kPa Measured by Fibroscan
timeFrame: Within 28 days in connection with their annual evaluation at a single point of time
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Stockholm CF Center, Karolinska University Hospital
name: Ferenc Karpati, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00842166: Surveillance of Summer Febrile Syndromes of Viral Origin in South of France
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Summer Febrile Syndromes of Viral Origin
Lead sponsor: Assistance Publique Hopitaux De Marseille
Sponsor class: OTHER
First posted: 2009-02-12
Enrollment: 90
Sex: ALL
Minimum age (years): 5
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The aim is to document viral etiologies of isolated fevers and inlfuenza-like syndromes during summertime in South of France in order to better understand the role of known vector-borne viruses such as Toscana virus, West Nile virus during seasonal activity of the arthropod vector. In each of the four cities, a network of general practitioners will be associated in the project to recruit patients who are not hospitalized. The combined involvement of infectious disease specialists and general practitioner will augment the range of patients (mild disease and sever cases) in the study.


Eligibility criteria: Inclusion Criteria:

* Old: equal to or higher than 5 years Living in the south of France, without voyage abroad in the 2 weeks preceding inclusion Presenting a fever or a syndrome pseudogripal since less than 7 days without diagnostic orientation nor infectious pathology of body,
* Affiliated with a mode of social security
* After obtaining free and informed of the written assent

Exclusion Criteria:

* Subject whose adhesion with the protocol is improbable according to the investigator
* Expectant mother
* Subject taking part in another clinical trial or in period of exclusion of a preceding clinical trial infectious
* Pathology of body requiring a specific treatment
* Discovered after inclusion d' a pregnancy

Primary outcomes:
measure: to document viral etiologies of isolated fevers and inlfuenza-like syndromes during summertime in South of France
timeFrame: 3 years
Secondary outcomes:
measure: Identification and characterization of emergent viruses responsible for estival fever in the south of France
timeFrame: 3years
Other outcomes:
Locations:
city: Marseille
country: France
facility: Service des Maladies Infectieuses et Tropicales de l'Hôpital Nord, AP-HM
Study officials:
affiliation: Assistance Publique Hopitaux De Marseille
name: REMI CHARREL
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02677766: Occupational Therapy in Complex Patients: a Pilot Study
Official title: Occupational Therapy in Complex Patients: a Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Complex Patients in Rehabilitation Phase
Keywords: Occupational Therapy
Complex patients
Randomized controlled trial
Occupational performance problem
Rehabilitation Complexity Scale
Lead sponsor: University of Modena and Reggio Emilia
Sponsor class: OTHER
Collaborators: name: Azienda USL Reggio Emilia - IRCCS
First posted: 2016-02-09
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To date, there are no studies that demonstrate that the intervention of Occupational Therapy (OT) in patients considered to be complex, regardless of diagnosis, could improve clinical and functional outcome for the patient. For this reason, the investigators propose one randomized controlled trial that will compare the group receiving the intervention of OT and the control group, to quantify the level of performance and satisfaction in the activities of interest of the patient, identified through the COPM. The hypothesis is that the benefit may be higher, as clinically relevant, in the group of complex patients treated with the proposed intervention of OT compared to those receiving the usual rehabilitation therapy.

Detailed description: The investigators already implemented an observational pilot study, aimed at defining the characteristics and needs of the population in question and the OT intervention characteristics. These information will now be used to implement this randomized controlled trial, designed to demonstrate the effectiveness of the OT intervention on the basis of clinically relevant outcome measures.

This study will be set with exploratory purposes, with appropriate high number, which will allow the investigators to quantify the difference between the two groups in terms of performance scores derived from the COPM (COPM_p). From the results of this part it will then depend on the planning for the subsequent study with the correct sample size.

Eligibility criteria: Inclusion Criteria:

* complex inpatient

Exclusion Criteria:

* primary psychiatric disorders,
* language barriers,
* severe cognitive impairment
* communication disability

Primary outcomes:
measure: Change From Baseline to Follow-up of the Performance Score at the Canadian Occupational Performance Measure
timeFrame: T0 is the baseline at the patient ammission in the rehabilitation Ward; T2 is the follow-up at end of the intervention, 45 days ± 15 days from discharge
Secondary outcomes:
Other outcomes:
Locations:
city: Reggio Emilia
country: Italy
facility: Arcispedale Santa Maria Nuova
state: RE
Study officials:
References:
citation: Pellegrini M, Formisano D, Bucciarelli V, Schiavi M, Fugazzaro S, Costi S. Occupational Therapy in Complex Patients: A Pilot Randomized Controlled Trial. Occup Ther Int. 2018 Sep 3;2018:3081094. doi: 10.1155/2018/3081094. eCollection 2018.
Clinical trial NCT00571766: Effects of Oral L-Arginine on Chronic Hypertension in Pregnancy
Official title: Effects of Oral L-Arginine on Chronic Hypertension in Pregnancy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Hypertension in Pregnancy
Keywords: chronic hypertension in pregnancy
chronic Hypertension
Lead sponsor: University of Modena and Reggio Emilia
Sponsor class: OTHER
First posted: 2007-12-12
Enrollment: 80
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the effects of oral L-Arginine in pregnant women with chronic hypertension.


Eligibility criteria: Inclusion Criteria:

* Pregnant women between 18-20 week of gestation with chronic hypertension

Exclusion Criteria:

* Maternal or fetal disease

Primary outcomes:
measure: to evaluate blood pressure changes in pregnant women with chronic hypertension during oral arginine or placebo treatment in second trimester of gestation.
timeFrame: 14 weeks
Secondary outcomes:
measure: To evaluate if is necessary add a conventional therapy for hypertension, to evaluate the maternal and fetal outcomes and possible complications, to evaluate the safety of L-Arginine.
timeFrame: 14 weeks
Other outcomes:
Locations:
city: Modena
country: Italy
facility: University of Modena and Reggio Emilia
state: Emilia Romagna
Study officials:
affiliation: University of Modena and Reggio Emilia
name: Fabio Facchinetti, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05077566: Immediate Exercise-Induced Hypoalgesia in Patients With Chronic Low Back Pain
Official title: Immediate Exercise-Induced Hypoalgesia in Patients With Chronic Low Back Pain
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Low Back Pain
Lead sponsor: Aveiro University
Sponsor class: OTHER
First posted: 2021-10-14
Enrollment: 83
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The main objective of this study is:

• To evaluate the immediate hypoalgesic effect of an aerobic exercise session of different intensities in patients with chronic low back pain;

The secondary objective is:

• To explore whether pain intensity, level of physical activity, functionality, catastrophizing, kinesiophobia, anxiety and depression interfere with the immediate hypoalgesic effect of exercise.

Detailed description: There will be 3 groups of participants, an asymptomatic control group that will not perform any exercise and two groups of individuals with low back pain. One group will perform exercise at 90% VO2máx and the other at 60% VO2máx.

All the three groups will be assessed at baseline for pressure pain threshold, pain intensity, pain phenotype, disability, kinesiophobia, catastrophizing, anxiety and depression, physical activity, and aerobic capacity. In addition, pressure pain threshold and pain intensity will also be assessed at post-intervention.

Eligibility criteria: Inclusion Criteria:

* All groups:
* age between 18 and 65 years old
* Participants with low back pain:
* non-specific LBP (defined as pain between the costal margins and the inferior gluteal folds, which is usually accompanied by painful limitation of movement and may be associated with pain referred down to the leg)

Exclusion Criteria:

* All groups:
* presence of pathology of the nervous system, cardiovascular or carcinogenic, rheumatic diseases (for example, rheumatoid arthritis), fibromyalgia, previous history of lumbar surgery, medication that affects or alters heart rate, any contraindication to exercise and pregnancy.

Primary outcomes:
measure: Pressure pain threshold
timeFrame: Baseline
measure: Pressure pain threshold
timeFrame: Post-intervention (approximately 45 minutes after baseline)
Secondary outcomes:
measure: Aerobic capacity
timeFrame: Baseline
measure: Physical activity
timeFrame: Baseline
measure: Anxiety and depression
timeFrame: Baseline
measure: Catastrophizing
timeFrame: Baseline
measure: Fear of movement
timeFrame: Baseline
measure: Disability
timeFrame: Base
measure: Pain phenotype
timeFrame: Baseline
measure: Symptoms of central sensitization
timeFrame: Baseline
measure: Pain intensity
timeFrame: Baseline
measure: Pain intensity
timeFrame: Post-intervention (approximately 45 minutes after baseline)
Other outcomes:
Locations:
city: Aveiro
country: Portugal
facility: Private Clinics of Physiotherapy
Study officials:
References:
Clinical trial NCT06811766: Comparative Effects of Strain-counterstrain and Muscle Energy Techniques on Neck Pain and Functional Disability in Patients with Cervicogenic Headache
Official title: Comparative Effects of Strain-counterstrain and Muscle Energy Techniques on Neck Pain and Functional Disability in Patients with Cervicogenic Headache
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Cervicogenic Headache
Keywords: CGH
SCS
METs
Lead sponsor: University of Faisalabad
Sponsor class: OTHER
First posted: 2025-02-06
Enrollment: 54
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: There will be two groups. Each group will receive different treatment techniques.
Primary purpose: TREATMENT

Brief summary: The primary objective of this study is to compare effects of SCS and METs on reduction of neck pain intensity and improvement in functional disability in individuals with CGH. The secondary objective is to assess the impact of both techniques on ROM in cervical spine


Eligibility criteria: Inclusion Criteria:

* participants who fulfill the criteria of international headache society.

Exclusion Criteria:

* participants who have cervicogenic headache after cervical injury or head surgery.

Primary outcomes:
measure: Visual analogue scale
timeFrame: 3 weeks
measure: Neck disability index
timeFrame: 3 weeks
Secondary outcomes:
measure: Goniometer
timeFrame: 3 weeks
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06606366: Study on the Contribution of the Genetic Tumor Profile Obtained by Circulating Tumor DNA Analysis in the Multidisciplinary Molecular Biology Meeting of Eastern PACA
Official title: Study on the Contribution of the Genetic Tumor Profile Obtained by Circulating Tumor DNA Analysis in the Multidisciplinary Molecular Biology Meeting of Eastern PACA
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Neoplasm Malignant
Keywords: Liquid biopsy
Lead sponsor: Centre Antoine Lacassagne
Sponsor class: OTHER
First posted: 2024-09-23
Enrollment: 238
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This study will evaluate the diagnostic performance of liquid biopsy for identifying molecular abnormalities among patients managed by the Multidisciplinary Molecular Biology Meeting. The gold standard considered in this study is the solid biopsy.


Eligibility criteria: Inclusion Criteria:

* Over 18 years old.
* Advanced-stage malignant solid tumor managed in a non-curative context.
* Patient eligible for Multidisciplinary molecular biology meeting with available archived tumor material (frozen or FFPE block, less than 5 years old) or a biopsiable tumor lesion.
* Performance status of 0 or 1.
* Patient able to read, write, and understand the French language.
* Patient has read the information sheet and signed the informed consent.
* Patient has social security coverage.

Exclusion Criteria:

* Previous or concurrent cancer diagnosed or treated within the last 5 years, except for in situ carcinoma of the cervix, basal cell or squamous cell carcinoma of the skin, and adequately treated in situ carcinoma of the bladder.
* Severe or uncontrolled systemic disease.
* Any condition which, in the investigator's judgment (geographical, social, or psychological factors, etc.), makes the patient unable to comply with study follow-up and procedures.
* Patient considered a vulnerable person; vulnerable persons are defined in Articles L1121-5 to L1121-8:

  * Pregnant women, women in labor, and breastfeeding mothers,
  * Persons deprived of liberty by judicial or administrative decision, individuals hospitalized without consent under Articles L. 3212-1 and L. 3213-1 who do not fall under the provisions of Article L. 1121-8,
  * Persons admitted to a healthcare or social institution for reasons other than research,
  * Adults unable to give their consent.

Primary outcomes:
measure: Sensitivity of liquid biopsy versus solid biopsy (gold standard)
timeFrame: 1 month
Secondary outcomes:
measure: Specificity of liquid biopsy versus solid biopsy (gold standard)
timeFrame: 1 month
measure: Failure rate of molecular screening
timeFrame: 1 month
measure: Clinical factors predictive of the sensitivity of liquid biopsy.
timeFrame: 1 month
measure: Rate of unexploitable results
timeFrame: 1 month
measure: Time required to obtain each analysis
timeFrame: 1 month
Other outcomes:
Locations:
city: Nice
country: France
facility: Centre Antoine Lacassagne
Study officials:
References: